BGN and atherosclerosis: Similarly, biglycan has been shown to be protective in a mouse model of atherosclerosis, where APOE-deficient mice, also deficient in biglycan, displayed enhanced circulating thrombin levels, elevated platelet activation and increased adhesion in vivo compared to control APOE knockouts [44].